Vaccines, In Brief: Meningitis B Recommendation Limited To High-Risk Groups
This article was originally published in The Pink Sheet Daily
Executive Summary
Also, CDC advisory committee withdraws preferred status for AstraZeneca’s FluMist in children and adds Merck’s Gardasil 9 to recommendations for HPV vaccination.
You may also be interested in...
Merck’s Gardasil Adds Serotypes; Boosting Vaccinations Seems Bigger Challenge
Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.